SCHEMBL259304

SCHEMBL259304

COc1cccc(-c2nc3c(oc4ncccc43)c(=O)[nH]2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.54
AURKA O14965 1/20 0.51
PIM1 P11309 2/20 0.47
CSNK2A2 P19784 2/20 0.47
CSNK2B P67870 2/20 0.47
PIM3 Q86V86 2/20 0.47
PIM2 Q9P1W9 2/20 0.47
TNKS O95271 2/20 0.45
PARP1 P09874 2/20 0.45
TNKS2 Q9H2K2 2/20 0.45
NR1I2 O75469 1/20 0.45
CYP1A2 P05177 1/20 0.45
VDR P11473 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2B6 P20813 1/20 0.45
AHR P35869 1/20 0.45
NR1I3 Q14994 1/20 0.45
ALDH1A1 P00352 1/20 0.45
F2 P00734 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259307 0.88 TNKS2 (0.56) PIK3CAAURKAPIM1CSNK2A2CSNK2B
SCHEMBL259059 0.88 ALDH1A1 (0.48) PIK3CAAURKAPARP1ALDH1A1
SCHEMBL259214 0.83 TNKS (0.49) PIK3CAPIM1CSNK2A2CSNK2BPIM3
SCHEMBL13318641 0.83 PIM3 (0.41) PIK3CAPIM1CSNK2A2CSNK2BPIM3
SCHEMBL259276 0.80 GUSB (0.56) TNKSPARP1TNKS2CYP1A2CYP2C9
SCHEMBL259271 0.79 PIM1 (0.44) PIK3CAPIM1CSNK2A2CSNK2BPIM3
SCHEMBL259377 0.78 CSNK2A2 (0.61) AURKAPIM1CSNK2A2CSNK2BPIM3
SCHEMBL12660728 0.78 CSNK2B (0.58) PIM1CSNK2A2CSNK2BPIM3PIM2
SCHEMBL259329 0.78 TNKS (0.42) PIM1CSNK2A2CSNK2BPIM3PIM2
SCHEMBL259317 0.77 AURKA (0.60) AURKAHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885AURKA 113/4885PIM1 865/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885AURKA 113/4885PIM1 865/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885AURKA 113/4885PIM1 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.